跳至主要内容
临床试验/NCT04522960
NCT04522960Unknown不适用

Melatonin in Alzheimer's Disease: Effect on Disease Progression and Epileptiform Activity.

Universitair Ziekenhuis Brussel2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年10月20日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
2
主要终点
Blood, saliva and urine melatonin correlations

研究概览

简要总结

This is a long-term, prospective, observational study to investigate and compare the levels and rhythm of melatonin in patients with AD dementia, mild cognitive impairment due to AD and healthy volunteers. The investigators would like to validate the use of salivary and urine melatonin measurements as an alternative for blood/CSF melatonin. Furthermore, the investigators would like to assess the effects of melatonin levels on cognition by correlating the levels and changes on cognitive tasks over a two year time frame. The investigators will also investigate whether these effects could be due to its anticonvulsive properties.

详细描述

Melatonin production gets disrupted in AD, as shown in post-mortem pineal glands and CSF of AD patients. CSF melatonin levels are known to significantly drop in patients with Alzheimer's dementia. It is known that CSF melatonin levels are much higher than blood melatonin levels, due to melatonin secretion from the pineal recess directly into the third ventricle. It has never been investigated whether blood melatonin accurately correlates with CSF melatonin in AD, nor whether saliva or urine melatonin levels accurately reflect blood/CSF melatonin in the AD continuum. The investigators want to validate the use of blood, saliva and urine melatonin levels as alternative for CSF melatonin in the AD continuum to pave the way for further use of less invasive collection techniques (blood, saliva, urine instead of CSF) and to possibly study circadian rhythm in a less disrupting, in home environment (saliva, urine).

Furhtermore, melatonin exerts several potential anti-AD properties, including anti-inflammatory, anti-oxidant, tilting APP processing towards the non-amyloidogenic pathway, exerting positive effects on sleep and so on. In vivo studies furthermore point to anticonvulsive and antiepileptic effects of melatonin in a whole range of rodent models. Some evidence exists for a role of melatonin in prevention of epileptic seizures in humans.

The investigators want to investigate influence of melatonin on changes in cognition in a longitudinal way, and investigate influence on (sub)clinical epileptiform activity.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Dementia due to AD, according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria
  • MCI due to AD, according to NIA-AA criteria
  • Healthy controls: Age- and gender matched healthy controls

排除标准

  • Patients (AD dementia, MCI)
  • Age < 18 years old
  • Pregnancy
  • Expected death due to illness within 2 years
  • Pacemaker or other ferrromagnetic material that is not MRI compatible
  • Other neurodegenerative or cerebrovascular disease
  • Pattern compatible with NPH (clinically, imaging)
  • Multiple sclerosis or other demyelinating disease
  • Depression, psychosis or other mental disease
  • Use of anti-epileptic drugs
  • Alcohol or substance abuse
  • Korsakoff syndrome
  • Symptomatic liver disease
  • Uncontrolled thyroid disorders
  • Untreated HIV or syphilis
  • Clinically significant vitamin B12 deficiency
  • Severe systemic medical illness (eg end-stage cardiac disease, ...)
  • Use of melatonin, agomelatine, or other sleep medications
  • Night worker
  • REM sleep behavior disorder, OSAS
  • Healthy controls
  • Age < 18 years old
  • Pregnancy
  • Pacemaker or other ferromagnetic material that is not MRI compatible
  • Mild cognitive impairment or dementia of any cause
  • Multiple sclerosis or other demyelinating disease
  • Depression, psychosis or other mental disease
  • Use of anti-epileptic drugs
  • Alcohol or substance abuse
  • Symptomatic liver disease
  • Uncontrolled thyroid disorders
  • Untreated HIV or syphilis
  • Clinically significant vitamin B12 deficiency
  • Severe systemic medical illness (eg end-stage cardiac disease, ...)
  • Use of melatonin, agomelatine, or other sleep medications
  • Night worker
  • REM sleep behavior disorder, OSAS

结局指标

主要结局

Blood, saliva and urine melatonin correlations

时间窗: 24 hours

Correlation between blood melatonin and urinary and salivary melatonin in the AD continuum

Melatonin influence on cognition

时间窗: 2 years

Correlations between melatonin levels and cognitive performance over a 2 year time frame. This will be assessed by use of neuropsychological testing including MMSE, MoCA, RBANS, VAT, ...

CSF and blood melatonin levels in patients with AD dementia, MCI due to AD and healthy volunteers

时间窗: 24 hours

Comparison of CSF and blood melatonin levels between patients with MCI and dementia due to AD and healthy volunteers.

Melatonin influence on epileptiform activity

时间窗: 8 weeks

Correlations between melatonin levels and (subclinical) epileptiform activity. Over a time frame of 8 weeks patients will undergo neuropsychological testing (with MMSE, MoCA, RBANS, VAT...), LTM-EEG monitoring (during 24 hours), MEG + hdEEG.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验